Posted by Michael Wonder on 09 May 2017
Pan-Canadian Oncology Drug Review recommendation supports the use of Tagrisso (osimertinib) as the standard of care for T790M mutated non-small-cell lung cancer
8 May 2017 - AstraZeneca is committed to rapid and collaborative discussions with pan-Canadian Pharmaceutical Alliance and provinces to get Tagrisso to Canadian patients.
AstraZeneca applauds the pan-Canadian Oncology Drug Review (pCODR) for its overwhelmingly positive clinical recommendation of the reimbursement of Tagrisso (osimertinib), a novel, targeted treatment for a subset of non-small cell lung cancer (NSCLC) patients.
Tagrisso is the first and only oral, targeted therapy shown to shrink tumour size and slow disease progression in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC who have progressed on or after EGFR tyrosine kinase inhibitor therapy.
